BMS receives offer from Taisho to purchase UPSA30 Dec 2018
The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.
Taisho Pharmaceutical Holdings has offered to purchase Bristol-Myers Squibb’s UPSA consumer health business for $1.6 billion.
UPSA develops and delivers important consumer medicines for patients in France, across Europe and additional countries. Taisho is the largest OTC drug company in Japan, with over a century of experience in this field. Taisho holds a leading presence in anti-inflammatory analgesic, cold and flu and hair growth segments in Japan and Southeast Asia. The potential transaction is anticipated to be completed during the first half of 2019, subject to regulatory approvals and satisfaction of certain other customary closing conditions.
“This announcement marks the culmination of an in-depth strategic review to identify the best option to grow the UPSA business for the long-term,” said Giovanni Caforio, chairman and chief executive officer of BMS. “UPSA is a strong business that deserves the best possible opportunities for its employees and its future development. With Taisho we have found an experienced and reliable buyer with the strategic interest to successfully sustain and grow the business for the future.”
BMS and Taisho have a history of conducting successful transactions. In 2009, Taisho entered the OTC market in certain Asian countries through the purchase of PT Squibb Indonesia from BMS. The subsidiary of Taisho is now known as PT Taisho Pharmaceuticals Indonesia Tbk.
UPSA is a French pharmaceutical company and brand owned by Bristol-Myers Squibb. Since 1935, UPSA has built its expertise in the development and manufacturing of pharmaceutical drugs and supplements for everyday ailments. Its portfolio covers a wide range of therapeutic areas: pain, cough & cold, vitamins and supplements, gastrointestinal and sleep.
Over the past several years, BMS has been realigning its business portfolio to address changes in its business and the future requirements of its evolving pipeline. The company is focusing resources on its highest priorities of discovering, developing and delivering transformational medicines for patients facing serious diseases. UPSA is focused on consumer medicines that are outside of the BMS core focus.
Specialist API CDMO acquired by GHO Capital
16 Mar 2019
Future plan is to extend Sterling’s international presence to meet increasing demand from customers worldwide.Read more
Bringing next generation single-use sensor technologies to the life science market
14 Mar 2019
Pall and Broadley-James’ combined expertise proves complementary in addressing critical customer pain points in modern bioprocessing.Read more
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy
13 Mar 2019
Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.Read more
TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program
12 Mar 2019
Trace Histories is a purpose-built distributed ledger solution for ensuring patient safety by 2023 DSCSA deadline.Read more
Overcoming lyophilization challenges at Interphex 2019
10 Mar 2019
Line of Sight approach to freeze-drying enables organizations to bring pharmaceutical products safely and quickly to market.Read more
Catalent invests over $27 million to commercialize Zydis Ultra
7 Mar 2019
Zydis Ultra allows a patented and innovative drug coating to be introduced during a product’s formulation, enabling the dosage of active ingredient to be up to four times higher than a conventional Zydis ODT.Read more
Novel systems for membrane chromatography
6 Mar 2019
Optimally run membrane chromatography processes will provide higher productivity, smaller-scale operations and increased robustness.Read more
Lilly to introduce lower-priced insulin
5 Mar 2019
Authorized generic version of Humalog will be available in US pharmacies at 50% lower list price.Read more
Biogen acquisition boosts its ophthalmology pipeline
4 Mar 2019
Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.Read more
Uniqsis expands LED photoreactor range
3 Mar 2019
The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation